Abstract
More than 10 years after publication of the first randomised trial to assess drug-eluting stents (DES) in patients with coronary artery disease,1 many studies have helped to clarify the advantages and limitations of first-generation DES. Despite having high antirestenotic efficacy in the first year after implantation, first-generation DES are associated with a delayed healing effect, leading to increased risk of late stent thrombosis2 and a decrease in antirestenotic efficacy over time,3 which has affected acceptance and stimulated the search for better successors.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
